Some six months on from its last acquisition, US pharma giant Merck & Co (NYSE: MRK) has announced that it is to acquire VelosBio for $2.75 billion.
San Diego-based VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1).
"At Merck, we continue to bolster our growing oncology pipeline with strategic acquisitions"VelosBio’s lead candidate is VLS-101, an antibody-drug conjugate targeting ROR1 that is currently being evaluated in a Phase I and a Phase II trial for the treatment of patients with hematologic malignancies and solid tumors, respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze